

Published in final edited form as:

Pediatr Res. 2010 October ; 68(4): 292–297. doi:10.1203/PDR.0b013e3181ed8609.

Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency

Nahid Waleh, Ryan Hodnick, Nami Jhaveri, Suzanne McConaghy, John Dagle, Steven Seidner, Donald McCurnin, Jeffrey C. Murray, Robin Ohls, and Ronald I. Clyman

Pharmaceutical Discovery Division [N.W.], SRI International, Menlo Park, CA 94025; Department of Pediatrics [R.H., S.M., R.O.], University of New Mexico, Albuquerque, New Mexico, 87131; Department of Pediatrics [N.J., R.I.C.], Cardiovascular Research Institute, University of California San Francisco, CA 94143; Department of Pediatrics [J.D., J.C.M.], University of Iowa, Iowa City, IA 52242; Department of Pediatrics [S.S., D.M.], University of Texas, Health Science Center, San Antonio, TX, 78229; Southwest Foundation for Biomedical Research [D.M.], San Antonio TX, 78227

Abstract

Three independent risk factors (*immature gestation*, *absence of antenatal glucocorticoid exposure*, and presence of the *rs2817399(A)* allele of the gene *TFAP2B*) are associated with PDAs that fail to close during prostaglandin inhibition. We hypothesized that these three factors may affect a common set of genes that increase the risk of persistent PDA after birth. We studied baboon ductus from term, preterm, and glucocorticoid-treated preterm fetuses, and found that both *immature gestation* and *absence of antenatal glucocorticoid exposure* decreased RNA expression of calcium- and potassium-channel genes involved in oxygen-induced constriction, and phosphodiesterase genes (that modulate cAMP/cGMP signaling). Ductus obtained from 2nd trimester human pregnancies were genotyped for *TFAP2B* polymorphisms. When present, the *rs2817399(A)* allele also was associated with decreased expression of calcium- and potassium-channel genes. In contrast, alleles of two other *TFAP2B* polymorphisms, *rs2817419(G)* and *rs2635727(T)*, which are not related to the incidence of PDA after birth, had no effect on RNA expression. In conclusion, three calcium- and potassium-channel genes (*CACNA1G/alpha1G*, *CACNB2/CaL-beta2*, and *KCNA2/Kv1.2*) were similarly affected by each of the PDA risk factors. We speculate that these channels may play a significant role in closing the preterm ductus during prostaglandin inhibition and may be potential targets for future pharmacologic manipulations.

Introduction

In contrast with the full term newborn, preterm infants frequently fail to close their ductus arteriosus after birth. Persistent ductus patency alters mesenteric blood flow, impairs pulmonary mechanics, increases the risk of pulmonary hemorrhage, and prolongs the need for mechanical ventilation (1,2).

Address for correspondence: Ronald Clyman, MD, University of California San Francisco, 513 Parnassus Ave., Room 1408 HSW, UCSF Box 0544, San Francisco, CA 94143-0544, 415-476-4462; FAX 415-502-2993, clymanr@peds.ucsf.edu.

Publisher's Disclaimer: *Pediatric Research Articles Ahead of Print* contains articles in unedited manuscript form that have been peer-reviewed and accepted for publication. As a service to our readers, we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting and review of the resulting proof before it is published in its final definitive form. Please note that during the production process errors may be discovered, which could affect the content, and all legal disclaimers that apply to the journal pertain.

In preterm infants, persistent ductus patency appears to be the result of alterations in the balance between developmentally regulated vasoconstricting and vasodilating pathways. Alterations in prostaglandin signaling seem to account for most persistent patent ductus arteriosus (PDA); 70% of preterm infants will close their PDA when prostaglandin production is inhibited by indomethacin or ibuprofen. However, approximately 30 % of PDAs are the result of factors that are independent of prostaglandin signaling. In these infants, the PDAs fail to close when prostaglandin production is inhibited (3,4). Discovering the pathways that prevent ductus closure (when prostaglandin signaling is not involved) may lead to the development of new therapeutic approaches.

We recently identified 3 perinatal/neonatal risk factors that are independent of each other, and predict the presence of PDAs that fail to close when prostaglandin signaling is inhibited (5): 1) *immature gestation* at birth, 2) *absence of antenatal glucocorticoid exposure*, and 3) *racial/genetic variation* (5). We hypothesized that these environmental (*immature gestation* and *absence of antenatal glucocorticoid exposure*) and genetic risk factors may be associated with altered mRNA expression of genes that are important for ductus constriction. We also hypothesized that these 3 independent risk factors may affect mRNA expression of a common set of genes, making their combined presence more likely to increase the risk of PDA after birth.

We designed the following studies to identify genes from both human and non-human primates that are affected by gestation, antenatal glucocorticoid exposure, and genetic variation. We focused our attention on the expression of genes that have been found to play an important role in ductus contractility in other species (6–18). We used non-human primates to study the effects of advancing gestation and antenatal glucocorticoids on ductus mRNA expression.

To study the role of genetic variation, we examined the influence of single nucleotide polymorphisms (SNPs) on the mRNA expression of genes that regulate human ductus contractility. Several genes have sequence polymorphisms that have been associated with the presence of isolated (nonsyndromic) PDAs in preterm infants: *AGTR1*/angiotensin II type 1 receptor (19), *IFNG/IFN γ* (20), estrogen receptor- α PvuII pP (21), *TFAP2B*/transcription factor AP-2 beta, *PTGIS*/prostacyclin synthase, and *TRAF1* (22). We examined SNPs in the gene *TFAP2B* since polymorphisms in this gene appear to act in concert with premature birth to delay ductus closure (see Discussion) (9,13,22).

We were particularly interested in genes expressed in the ductus arteriosus that were similarly affected by all 3 risk factors (*immature gestation*, *absence of glucocorticoid exposure*, and *TFAP2B DNA polymorphisms*) since they might represent common targets for future pharmacologic manipulations.

Methods

Tissue

Studies involving baboons (*Papio papio*) were performed at the Southwest National Primate Research Center, Southwest Foundation for Biomedical Research in San Antonio, TX. Study procedures were approved by the Institutional Animal Care and Use Committee. Details of animal care have been published elsewhere (23–25). Briefly, fetuses from time-dated pregnant dams were delivered by elective caesarean section (at either 125 \pm 2 (n=20) or 175 \pm 2 (n=10) days gestation; full term = 185 days) and euthanized at the time of delivery. Ten of the dams were treated with 6 mg of intramuscular betamethasone 48 and 24 h before elective delivery at 125 \pm 2 days gestation.

Human tissue was obtained under the oversight of the Institutional Review Board at University of New Mexico (which determined that the study did not constitute human subject research since no identifiable patient data were collected). Mid-gestation (11–22 wk, n = 57) human fetal ductus arteriosus and ascending aorta were obtained at elective terminations of pregnancy in healthy women. Prostaglandins were not used during the terminations. Cervical ripening was performed using laminaria (compressed seaweed). Ductus and aorta samples were isolated and snap frozen in liquid nitrogen within 30 minutes of termination. Gestational age was determined by fetal foot length (26).

Preparation of total RNA, reverse transcription and quantitative polymerase chain reaction

Total RNA was isolated from each individual ductus as described elsewhere (27). We used the TaqMan Universal PCR master mix of PE Applied Biosystems (Foster City, CA) to quantify gene expression. Taqman probes were designed using the Primer Express program and labeled with fluorophores FAM (6-carboxy-fluorescein) and TAMRA (6 carboxy-tetramethyl-rhodamine) as reporter and quencher dyes, respectively. An ABI PRISM 7500 Sequence detection system was used to determine the cycle threshold (CT). Reactions were carried out in triplicates. Data were analyzed using the Sequence Detector version 1.6.3 program. The degree of expression of the gene of interest was determined using the relative gene expression method. Malate dehydrogenase (MDH) was used as an internal control to normalize the data (28). Δ CT represents the difference in cycle threshold (CT) between the expression of the housekeeping gene (MDH) and the gene of interest. Each unit of Δ CT represents a 2-fold change in a gene's mRNA. The more negative the Δ CT, the fewer the number of starting copies of a gene (mRNA).

DNA genotyping

DNA was extracted from the ascending aorta of each of human fetal samples using the QIAamp DNA mini kit (QIAGEN Inc, Valencia, CA). DNA was quantified spectrophotometrically. Allelic variation was determined by using the TaqMan genotyping system (Applied Biosystems, Foster City, CA), as previously described (29). Allele scoring was performed using the Sequence Detection Systems 2.2 software (Applied Biosystems). We studied several sequence polymorphisms of the *TFAP2B* gene because recent findings suggest that they may be associated with delayed ductus closure in preterm infants (22). The *TFAP2B* SNPs were selected using data from the International HapMap project (www.hapmap.org). To ensure that an adequate number of individuals within the population would be carriers of the minor allele, we chose a minor allele frequency of 0.1 as a lower cutoff for a SNP. We examined one *TFAP2B* SNP (rs2817399: A-allele) that has been positively associated with delayed ductus closure (even in the presence of indomethacin), with a P value of <0.01. We also examined two *TFAP2B* SNPs that are unrelated to the timing of ductus closure (rs2817419: G-allele, P>0.90; and, rs2635727: T-allele, P>0.90 for association with the development of a PDA) (22)(unpublished results, Dagle et al).

Statistics

Values are expressed as mean \pm standard deviation. The student t test was used to compare means. When appropriate, multivariate linear or logistic regression analyses were performed to determine the independent effects of gestational age, *TFAP2B* mRNA expression, and *TFAP2B* allele frequency on the mRNA expression of genes involved with ductus contractility. P <0.05 was considered statistically significant.

Results

Effects of immature gestation and antenatal glucocorticoid exposure on ductus arteriosus gene expression in fetal baboons

Immature gestation altered the mRNA expression of several baboon ductus genes that are involved in oxygen-induced constriction (calcium channels (*CACNA1G*/Ca-alpha1G, *CACNB2*/CaLbeta2, *CACNB3*/CaLbeta3), calcium pumps (*ATP2A3*/SERCA3), and Potassium-channels (*KCNA2*/Kv1.2, *KCNA5*/Kv1.5, *KCNB1*/Kv2.1, *KCNS3*/Kv9.3, *KCNAB2*/Kvbeta1.2, *KCNAB1*/Kvbeta1.3, *KCNMB1*/BKCa-beta1, *ABCC9*/SUR2)) (Table 1). The mRNA expression of several of the genes involved with endothelin signaling (*ECE1*, *EDNRA*/ETA-receptor), prostaglandin signaling (*PTGS1*/COX1, *PTGIS*/PGI2-synthase, phosphodiesterases 1B, 3A, 3B, 4D), contractile proteins (*CNN1*/Calponin, *CALD1*/Caldesmon, *TPM1*/Tropomyosin), and inflammation and remodeling (*EPAS1*/HIF2alpha, *PDGFB*/PDGF-B chain, *VEGFA*) were also altered by *immature gestation* (Table 1).

On the other hand, *immature gestation* had no effect on mRNA expression of the following genes: *CACNA1C*/CaLalpha1c, *SLC8A1*/NCX-1, *RHOA*, *RHOB*, *KCNMA1*/BKCa, *KCNJ8*/Kir6.1, *EDN1*/ET1, *EDNRB*/ETB-receptor, *PTGS2*/COX2, *PTGER2*/EP2, *PTGER3*/EP3, *PTGER4*/EP4, *PDE1C*, *CD40LG*/CD154, *NOS3*/eNOS, *HAS2*, *IFNG*/IFNgamma, *IL6*, *IL8*, *NOS2*/iNOS, *CSF1*/MCSF, *MMP2*, *MMP3*, *MMP9*, *TGFB3*/TGFbeta3, *TNF*/TNFalpha, *PLAU*/UPA, and *VCAM* (data not shown).

We were interested in identifying a set of genes whose expression was similarly affected by the risk factors *immature gestation* and absence of *antenatal glucocorticoid exposure* since both risk factors are associated with an increased incidence of ductus patency after birth. *Absence of antenatal glucocorticoid exposure* affected mRNA expression of a similar, but more limited, set of the same genes that were altered by *immature gestation* (Table 1). In particular, both *immature gestation* and *absence of antenatal glucocorticoid exposure* altered mRNA expression of calcium channel and potassium channel genes that are involved in oxygen-induced constriction, and phosphodiesterase genes that modulate second messenger (camp/cGMP) signaling.

Effects of genetic variations, or polymorphisms, on ductus arteriosus gene expression in human fetuses

We examined how genetic variations in the *TFAP2B* gene might alter mRNA expression of genes that were affected by both *immature gestation* and *absence of antenatal glucocorticoid exposure*. Because of the small size of the second trimester human ductus, we were limited in the number of candidate genes we could evaluate. Between 11 and 22 weeks of gestation, there was a significant increase in *TFAP2B* mRNA expression in the human ductus (for every 1 week increase in gestation, there was a 0.16 increase in *TFAP2B* Δ CT, $p=0.000$). Since *TFAP2B* mRNA expression was significantly linked to gestational age, we used a multivariate model (which included gestational age) to examine the independent effects of *TFAP2B* mRNA expression on the mRNA expression of the candidate genes that affect ductus contractility. We found a positive correlation between *TFAP2B* mRNA expression and the mRNA expression of most of the candidate genes we examined (even after controlling for gestation) (Table 2).

We genotyped the DNA of individual human ductus samples to determine the allele frequency of several *TFAP2B* polymorphisms. The A allele of the *TFAP2B* polymorphism *rs2817399* (which is associated with an increased incidence of PDA in preterm infants (22)(unpublished results, Dagle et al), was present in 25/57 (44%) of fetal ductus. Since expression of many of the candidate genes that alter ductus closure, are regulated by gestational age (Table 3), we used multivariate models (which included gestational age) to examine the independent effects

of the *rs2817399(A)*-allele on their mRNA expression. We found that the *rs2817399(A)*-allele was significantly associated with decreased mRNA expression of genes involved with oxygen-induced constriction of the ductus arteriosus: the *CACNB2*/calcium L-channel beta2 subunit, the *CACNA1G*/alpha1G (calcium T-channel), and the *KCNA2*/Kv1.2 potassium-channel (Table 2).

Alleles of two other *TFAP2B* polymorphisms, *rs2817419(G)* and *rs2635727(T)* (neither are associated with an increased incidence of PDA), were present in 20/57 (35%) and 19/57 (33%) of second trimester fetal ductus samples, respectively. In contrast to the *rs2817399(A)* allele, alleles of the two other *TFAP2B* polymorphisms, *rs2817419(G)* and *rs2635727(T)* were not associated with changes in candidate gene expression (Table 2).

Discussion

We hypothesized that different environmental and genetic risk factors may negatively impact a similar cohort of candidate genes involved in ductus closure. Recent findings support the concept that environmental risk factors (like *immature gestation* and *absence of antenatal glucocorticoid exposure*) directly affect ductus closure through mechanisms that are independent of prostaglandin signaling. Advancing gestation affects pathways that regulate intracellular calcium concentrations (15,17), and alters the sensitivity of ductus smooth muscle to vasodilators, like nitric oxide (4,30). Glucocorticoids, like advancing gestation, also affect intracellular calcium concentrations and alter the balance of vasodilators in the ductus (31–36). As a result, antenatal glucocorticoid exposure increases fetal ductus contractility even when prostaglandin production has already been inhibited (37). Our current experiments demonstrate that, in non-human primates, *immature gestation* and *absence of antenatal glucocorticoid exposure* alter the mRNA expression of calcium channel and potassium channel genes involved in oxygen-induced constriction, and phosphodiesterase genes that modulate cAMP/cGMP signaling (Tables 1).

To study the effects of genetic variation on candidate gene expression, we examined the *TFAP2B* gene since DNA polymorphisms in *TFAP2B* appear to act in concert with premature birth to delay ductus closure (22). *TFAP2B* is a member of the AP2 transcription factor family, a family of retinoic acid-responsive genes that play an important role in development, apoptosis, cell-cycle control, and complex morphogenic processes (38,39). *TFAP2B* is expressed in cells derived from the neural crest and is uniquely expressed in ductus smooth muscle (compared with the surrounding pulmonary artery and aorta) (9,40). *TFAP2B* regulates several genes that are important for ductus smooth muscle development in mice (e.g., calponin, endothelin and HIF2alpha). Targeted deletions of *TFAP2B* prevent the ductus from constricting in full term, newborn mice (9). Similarly, the dominant-negative mutations and intronic splicing mutations in *TFAP2B* (found in Char syndrome) prevent the ductus from constricting in full term human newborns (13,41).

TFAP2B mRNA is strongly expressed by the beginning of the third trimester, in the mouse ductus, and then declines towards term (9). We observed a similar pattern of *TFAP2B* expression in the baboon ductus during the third trimester (Table 1).

Our human studies utilized second trimester ductus. During the second trimester, there was a significant increase in *TFAP2B* mRNA expression in the human ductus. As has been observed in mice, *TFAP2B* mRNA expression was positively correlated with calponin, HIF2alpha and endothelin (endothelin converting enzyme) expression in the human ductus. We also observed a positive correlation between *TFAP2B* mRNA expression and the mRNA expression of several other genes that play important roles in ductus closure at birth (Table 2). The

significance of these relationships persisted, even when the effects of advancing gestational age were included in the statistical models (Table 2).

We used multivariate regression models to examine the independent effects of gestational age and genetic variation (in *TFAP2B*) on the mRNA expression of genes that affect ductus closure. We were particularly interested in the A-allele of the *TFAP2B* polymorphism *rs2817399* since it is associated with preterm PDAs that fail to close in the presence of indomethacin (22). The *rs2817399(A)-allele* is located between exons 4 and 5, where mutations reported to cause Char syndrome are located (41). The *rs2817399(A)-allele* is present in a haplotype block that encompasses most of the *TFAP2B* gene so that the actual genetic variations responsible for PDA in preterm infants could lie anywhere within this haplotype block. Detailed mapping of this region will be necessary to define the actual etiologic polymorphism.

We found that the *rs2817399(A)-allele* was significantly associated with decreased mRNA expression of 3 genes that could impact ductus closure after birth: *CACNB2* (the calcium L-channel beta2 subunit), *CACNA1G* (the alpha1G (calcium T-channel)), and *KCNA2* (the Kv1.2 potassium-channel) (Table 2) (6–8). To determine whether these changes were specific to the *rs2817399(A)-allele*, we examined two other *TFAP2B* polymorphisms, *rs2817419(G)* and *rs2635727(T)*, which are unrelated to the incidence of preterm PDA. Both polymorphisms are located beyond exon 7 (the last exon of the *TFAP2B* gene) where no known Char syndrome mutations have been reported (41). Neither polymorphism was associated with changes in any of the candidate genes' mRNA expression (Table 3).

Our findings provide biologic plausibility to the concept that *rs2817399(A)* is a functional polymorphism (or in tight association with a functional polymorphism), that plays an active role in regulating ductus contractility. At this time we do not have an explanation for the changes in calcium- and potassium-channel gene expression that occur in the presence of the *rs2817399(A)-allele*. The *rs2817399(A)-allele* was not associated with a decrease in *TFAP2B* mRNA expression (as detected by our Real-time PCR probe/primers sets) (Table 2). SNPs in or near a gene can affect both the amount and function of the mRNA or protein produced. Future studies will be needed to determine how this polymorphism affects the expression of downstream calcium- and potassium-channel genes.

Our hypothesis was that different environmental and genetic risk factors might negatively impact a similar cohort of genes involved in ductus closure. We found that the same calcium- and potassium-channel genes (*CACNB2*/calcium L-channel beta2 subunit, *CACNA1G*/alpha1G (calcium T-channel), and *KCNA2*/Kv1.2 potassium-channel) that were decreased in humans in the presence of the *TFAP2B* polymorphism *rs2817399(A)*, were also decreased in non-human primates when the two environmental risk factors (*immature gestation* and *absence of antenatal betamethasone exposure*) were present (Table 3). These 3 calcium- and potassium-channel genes have previously been shown to be involved with oxygen-induced constriction of the ductus arteriosus (6–8). We speculate that calcium- and potassium-channels may play a role in closing the preterm ductus during prostaglandin inhibition since they appear to be altered in PDAs that fail to respond to indomethacin treatment. If this proves to be the case, they may be potential targets for future pharmacologic manipulations. We also speculate that when several PDA risk factors are combined in the same infant, they may have a cumulative effect on the expression of calcium and potassium channels, that may delay ductus closure after birth (even when prostaglandin production has been inhibited). In the future, algorithms incorporating the combinatorial effects of these risk factors may enable a more targeted use of indomethacin or ibuprofen in infants with a PDA.

Acknowledgments

We are very grateful to Jackie Coalson, Vicki Winter, and personnel at the BPD Resource Centre for their help in obtaining baboon tissues, and to Michael Rowe and the staff at the Curtis Boyd Clinic for tissue collection at the University of New Mexico.

Financial Support: This work was supported by grants from U.S. Public Health Service (NIH grants HL46691, HL56061, HD52953 (JCM), HL52636 BPD Resource Center and P51RR13986 baboon facility support) and by a gift from the Jamie and Bobby Gates Foundation.

Abbreviations

PDA	patent ductus arteriosus
<i>TFAP2B</i>	transcription factor AP-2 beta
SNP	single nucleotide polymorphism
MDH	Malate dehydrogenase
CT	cycle threshold
Δ CT	the difference in cycle threshold between the expression of the housekeeping gene MDH and the gene of interest

Bibliography

1. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. *J Pediatr* 2007;150:216–219. [PubMed: 17307530]
2. McCurnin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. *Pediatrics* 2008;122:e1262–e1267. [PubMed: 19001037]
3. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. *N Engl J Med* 2001;344:1966–1972. [PubMed: 11430325]
4. Clyman RI, Waleh N, Black SM, Riemer RK, Mauray F, Chen YQ. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs. The role of gestation, oxygen tension and vasa vasorum. *Pediatr Res* 1998;43:633–644. [PubMed: 9585010]
5. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. *J Pediatr* 2007;151:629–634. [PubMed: 18035143]
6. Akaike T, Jin MH, Yokoyama U, Izumi-Nakaseko H, Jiao Q, Iwasaki S, Iwamoto M, Nishimaki S, Sato M, Yokota S, Kamiya Y, Adachi-Akahane S, Ishikawa Y, Minamisawa S. T-type Ca²⁺ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation. *J Biol Chem* 2009;284:24025–24034. [PubMed: 19567868]
7. Waleh N, Reese J, Kajino H, Roman C, Seidner S, McCurnin D, Clyman RI. Oxygen-induced tension in the sheep ductus arteriosus: effects of gestation on potassium and calcium channel regulation. *Pediatr Res* 2009;65:285–290. [PubMed: 19092721]
8. Reese J, Waleh N, Poole SD, Brown N, Roman C, Clyman RI. Chronic in utero cyclooxygenase inhibition alters PGE₂-regulated ductus arteriosus contractile pathways and prevents postnatal closure. *Pediatr Res* 2009;66:155–161. [PubMed: 19390487]
9. Ivey KN, Sutcliffe D, Richardson J, Clyman RI, Garcia JA, Srivastava D. Transcriptional regulation during development of the ductus arteriosus. *Circ Res* 2008;103:388–395. [PubMed: 18635823]
10. Liu H, Manganiello VC, Clyman RI. Expression, activity and function of cAMP and cGMP phosphodiesterases in the mature and immature ductus arteriosus. *Pediatr Res* 2008;64:477–481. [PubMed: 18552705]
11. Coceani F, Liu Y, Seidlitze E, Kelsey L, Kuwaki T, Ackerley C, Yanagisawa M. Endothelin A receptor is necessary for O₂ constriction but not closure of ductus arteriosus. *Am J Physiol* 1999;277:H1521–H1531. [PubMed: 10516191]

12. Costa M, Barogi S, Socci ND, Angeloni D, Maffei M, Baragatti B, Chiellini C, Grasso E, Cocceani F. Gene expression in ductus arteriosus and aorta: comparison of birth and oxygen effects. *Physiol Genomics* 2006;25:250–262. [PubMed: 16418320]
13. Zhao F, Weismann CG, Satoda M, Pierpont ME, Sweeney E, Thompson EM, Gelb BD. Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation. *Am J Hum Genet* 2001;69:695–703. [PubMed: 11505339]
14. Clyman RI, Waleh NS, Kajino H, Roman C, Mauray F. Calcium-dependent and calcium-sensitizing pathways in the mature and immature ductus arteriosus. *Am J Physiol Regul Integr Comp Physiol* 2007;293:R1650–R1656. [PubMed: 17652360]
15. Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry G, Moudgil R, Nakanishi T, Rebeyka I, Thébaud B, Michelakis ED, Archer SL. Oxygen Activates the Rho/Rho-Kinase Pathway and Induces RhoB and ROCK-1 Expression in Human and Rabbit Ductus Arteriosus by Increasing Mitochondria-Derived Reactive Oxygen Species. A Newly Recognized Mechanism for Sustaining Ductal Constriction. *Circulation* 2007;115:1777–1788. [PubMed: 17353442]
16. Hong Z, Hong F, Olschewski A, Cabrera JA, Varghese A, Nelson DP, Weir EK. Role of store-operated calcium channels and calcium sensitization in normoxic contraction of the ductus arteriosus. *Circulation* 2006;114:1372–1379. [PubMed: 16982938]
17. Thébaud B, Michelakis ED, Wu XC, Moudgil R, Kuzyk M, Dyck JR, Harry G, Hashimoto K, Haromy A, Rebeyka I, Archer SL. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. *Circulation* 2004;110:1372–1379. [PubMed: 15353504]
18. Thébaud B, Wu XC, Kajimoto H, Bonnet S, Hashimoto K, Michelakis ED, Archer SL. Developmental absence of the O₂ sensitivity of L-type calcium channels in preterm ductus arteriosus smooth muscle cells impairs O₂ constriction contributing to patent ductus arteriosus. *Pediatr Res* 2008;63:176–181. [PubMed: 18091358]
19. Treszl A, Szabo M, Dunai G, Nobilis A, Kocsis I, Machay T, Tulassay T, Vasarhelyi B. Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates. *Pediatr Res* 2003;54:753–755. [PubMed: 12904590]
20. Bokodi G, Derzbach L, Banyasz I, Tulassay T, Vasarhelyi B. Association of interferon gamma T +874A and interleukin 12 p40 promoter CTCTAA/GC polymorphism with the need for respiratory support and perinatal complications in low birthweight neonates. *Arch Dis Child Fetal Neonatal Ed* 2007;92:F25–F29. [PubMed: 16754651]
21. Derzbach L, Treszl A, Balogh A, Vasarhelyi B, Tulassay T, Rigo JJ. Gender dependent association between perinatal morbidity and estrogen receptor-alpha PvuII polymorphism. *J Perinat Med* 2005;33:461–462. [PubMed: 16238543]
22. Dagle JM, Lepp NT, Cooper ME, Schaa KL, Kelsey KJ, Orr KL, Caprau D, Zimmerman CR, Steffen KM, Johnson KJ, Marazita ML, Murray JC. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. *Pediatrics* 2009;123:1116–1123. [PubMed: 19336370]
23. Coalson JJ, Winter VT, Siler-Khodr T, Yoder BA. Neonatal chronic lung disease in extremely immature baboons. *Am J Respir Crit Care Med* 1999;160:1333–1346. [PubMed: 10508826]
24. Yoder BA, Siler-Khodr T, Winter VT, Coalson JJ. High-frequency oscillatory ventilation: effects on lung function, mechanics, and airway cytokines in the immature baboon model for neonatal chronic lung disease. *Am J Respir Crit Care Med* 2000;162:1867–1876. [PubMed: 11069828]
25. McCurnin DC, Yoder BA, Coalson J, Grubb P, Kerecman J, Kupferschmid J, Breuer C, Siler-Khodr T, Shaul PW, Clyman R. Effect of ductus ligation on cardiopulmonary function in premature baboons. *Am J Respir Crit Care Med* 2005;172:1569–1574. [PubMed: 16179644]
26. Merz E, Oberstein A, Wellek S. Age-related reference ranges for fetal foot length. *Ultraschall Med* 2000;21:79–85. [PubMed: 10838708]
27. Bouayad A, Kajino H, Waleh N, Fouron JC, Andelfinger G, Varma DR, Skoll A, Vazquez A, Gobeil F Jr, Clyman RI, Chemtob S. Characterization of PGE₂ receptors in fetal and newborn lamb ductus arteriosus. *Am J Physiol Heart Circ Physiol* 2001;280:H2342–H2349. [PubMed: 11299240]
28. Waleh N, Kajino H, Marrache AM, Ginzinger D, Roman C, Seidner SR, Moss TJ, Fouron JC, Vazquez-Tello A, Chemtob S, Clyman RI. Prostaglandin E₂--mediated relaxation of the ductus

- arteriosus: effects of gestational age on g protein-coupled receptor expression, signaling, and vasomotor control. *Circulation* 2004;110:2326–2332. [PubMed: 15477420]
29. Ehn NL, Cooper ME, Orr K, Shi M, Johnson MK, Caprau D, Dagle J, Steffen K, Johnson K, Marazita ML, Merrill D, Murray JC. Evaluation of fetal and maternal genetic variation in the progesterone receptor gene for contributions to preterm birth. *Pediatr Res* 2007;62:630–635. [PubMed: 17805208]
 30. Keller RL, Tacy TA, Fields S, Ofenstein JP, Aranda JV, Clyman RI. Combined treatment with a non-selective nitric oxide synthase inhibitor (L-NMMA) and indomethacin increases ductus constriction in extremely premature newborns. *Pediatr Res* 2005;58:1216–1221. [PubMed: 16306196]
 31. Roghair RD, Lamb FS, Miller FJ Jr, Scholz TD, Segar JL. Early gestation dexamethasone programs enhanced postnatal ovine coronary artery vascular reactivity. *Am J Physiol Regul Integr Comp Physiol* 2005;288:R46–R53. [PubMed: 15217789]
 32. Koshino Y, Hayashi T, Matsukawa S, Asazuma K, Eguchi K, Kato H, Nakai T, Miyamori I. Dexamethasone modulates the expression of endothelin-1 and -A receptors in A7r5 vascular smooth muscle cells. *J Cardiovasc Pharmacol* 1998;32:665–672. [PubMed: 9781938]
 33. Kornel L, Prancan AV, Kanamarlapudi N, Hynes J, Kuzianik E. Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca²⁺ influx in vascular smooth muscle in vivo. *Endocr Res* 1995;21:203–210. [PubMed: 7588382]
 34. Hayashi T, Nakai T, Miyabo S. Glucocorticoids increase Ca²⁺ uptake and [3H]dihydropyridine binding in A7r5 vascular smooth muscle cells. *Am J Physiol* 1991;261:C106–C114. [PubMed: 1650136]
 35. Brem AS, Bina RB, Mehta S, Marshall J. Glucocorticoids inhibit the expression of calcium-dependent potassium channels in vascular smooth muscle. *Mol Genet Metab* 1999;67:53–57. [PubMed: 10329024]
 36. Smith L, Smith JB. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. *J Biol Chem* 1994;269:27527–27531. [PubMed: 7961668]
 37. Takami T, Momma K, Imamura S. Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. *Circ J* 2005;69:354–358. [PubMed: 15731544]
 38. Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fassler R. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. *Genes Dev* 1997;11:1938–1948. [PubMed: 9271117]
 39. Moser M, Ruschhoff J, Buettner R. Comparative analysis of AP-2 alpha and AP-2 beta gene expression during murine embryogenesis. *Dev Dyn* 1997;208:115–124. [PubMed: 8989526]
 40. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. *Gene* 2000;260:1–12. [PubMed: 11137286]
 41. Mani A, Radhakrishnan J, Farhi A, Carew KS, Warnes CA, Nelson-Williams C, Day RW, Pober B, State MW, Lifton RP. Syndromic patent ductus arteriosus: evidence for haploinsufficient TFAP2B mutations and identification of a linked sleep disorder. *Proc Natl Acad Sci USA* 2005;102:2975–2979. [PubMed: 15684060]

Table 1

Effects of gestational age and antenatal betamethasone on Real Time polymerase chain reaction (PCR) measurements of genes involved with ductus arteriosus closure in fetal baboons

Fetal ductus from 125 days gestation baboons (not exposed to betamethasone in utero: 125d gestation, n=10 separate animals), were compared with ductus from 125 days gestation fetuses exposed to 48 hours of betamethasone prior to necropsy (125d + betamethasone, n=10 separate animals), and with ductus from 175 days gestation fetuses (not exposed to betamethasone in utero: 175d gestation, n=10 separate animals). Δ CT represents the difference in cycle threshold (CT) between the expression of the housekeeping gene Malate dehydrogenase (MDH) and the gene of interest. Each unit of Δ CT represents a 2-fold change in a gene's mRNA. The more negative the Δ CT, the fewer the number of starting copies of a gene (mRNA). **Immaturity:** Fetal ductus from 125 days gestation baboons were compared with ductus from 175 days gestation baboons. **Betamethasone:** Fetal ductus from 125 days gestation baboons, not exposed to betamethasone in utero, were compared with ductus from 125 days gestation baboons exposed to 48 hours of betamethasone prior to necropsy.

Gene	125d gestation		125d + betamethasone		175d gestation		Risk Factors	
	Δ CT		Δ CT		Δ CT		Immaturity	No betamethasone
	mean	sd	mean	sd	mean	sd	p<0.05	p<0.05
Ca++ signaling								
<i>CACNA1G</i> /Ca-alpha1G	-2.08	0.88	-1.35	0.72	-1.22	0.66	↓	↓
<i>CACNB2</i> /CaLbeta2	-0.68	0.88	0.55	0.97	0.90	0.67	↓	↓
<i>CACNB3</i> /CaLbeta3	-1.84	0.17	-1.90	0.20	-2.00	0.12	↑	-
<i>ATP2A3</i> /SERCA3	-3.28	1.09	-1.74	0.82	-1.40	0.72	↓	↓
K+ channels								
<i>KCN42</i> /Kv1.2	-3.34	1.37	-1.85	1.28	-1.16	0.92	↓	↓
<i>KCN45</i> /Kv1.5	1.15	0.22	1.04	0.46	0.75	0.22	↑	-
<i>KCNB1</i> /Kv2.1	-3.80	0.81	-3.30	0.74	-3.00	0.51	↓	-
<i>KCNS3</i> /Kv9.3	-6.51	1.60	-5.11	1.18	-4.72	1.05	↓	↓
<i>KCNAB2</i> /Kvbeta1.2	-5.10	1.25	-3.70	1.29	-3.34	0.82	↓	↓
<i>KCNAB1</i> /Kvbeta1.3	-3.02	1.21	-1.57	1.17	-1.29	0.81	↓	↓
<i>KCNMB1</i> /BKCa-beta1	-0.46	0.37	0.31	0.29	0.05	0.37	↓	↓
<i>ABCC9</i> /SUR2	-0.86	0.29	-1.18	0.38	-1.19	0.19	↑	-
Contractile proteins								
<i>CNN1</i> /Calponin	-3.78	0.37	-4.04	0.65	-2.54	0.25	↓	-
<i>CALD1</i> /Caldesmon	0.90	0.31	1.02	0.43	2.77	0.55	↓	-
<i>TPM1</i> /Tropomyosin	3.09	0.42	3.03	0.46	4.08	0.23	↓	-

Gene	125d gestation		125d + betamethasone		175d gestation		Risk Factors	
	ΔCT		ΔCT		ΔCT		Immaturity	No betamethasone
	mean	sd	mean	sd	mean	sd	p<0.05	p<0.05
Endothelin signaling								
<i>ECE1</i>	-7.45	0.65	-7.16	0.83	-6.79	0.81	↓	-
<i>EDNRA/ETA-receptor</i>	-1.03	0.36	-0.99	0.36	-0.56	0.64	↓	-
Prostaglandin signaling								
<i>PTGS1/COX1</i>	-2.75	0.70	-2.59	0.40	-2.05	0.62	↓	-
<i>PDE1B</i>	-3.80	2.52	-0.85	2.13	-0.50	1.26	↓	↓
<i>PDE3A</i>	-2.18	0.21	-2.08	0.33	-1.81	0.22	↓	-
<i>PDE3B</i>	-2.83	0.67	-2.10	0.82	-1.77	0.57	↓	↓
<i>PDE4D</i>	-4.19	0.45	-4.29	0.39	-3.61	0.35	↓	-
<i>PTGIS/PGI2-synthase</i>	2.38	0.31	2.46	0.45	2.83	0.38	↓	-
Inflammation/remodeling								
<i>EPAS1/HIF2alpha</i>	0.67	0.42	0.89	0.55	2.75	0.33	↓	-
<i>PDGFB/PDGF-B chain</i>	-2.78	0.90	-1.49	1.05	-1.13	0.66	↓	↓
<i>TFAP2B</i>	0.65	0.31	0.53	0.39	0.22	0.22	↑	-
<i>VEGFA</i>	0.37	0.19	0.07	0.46	1.66	0.48	↓	-

↑ greater than ΔCT of either the mature (175 days gestation) ductus or the immature ductus exposed to antenatal betamethasone; ↓ p<0.05, ΔCT of immature ductus is significantly less; - p>0.05, ΔCT of immature ductus is not significantly different.

Abbreviations: Ca-α1G, calcium T-channel; CaL, calcium L-channel; SERCA, sarcoplasmic reticulum Ca⁺⁺-ATPase; K channels (Kv, BKCa, Kir), potassium channels; ECE, endothelin converting enzyme; ETAreceptor, endothelin receptor A; COX, cyclooxygenase; PDE, phosphodiesterase; PTGIS, prostacyclin (PGI2)-synthase; HIF, hypoxia inducible factor; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor.

Table 2

Multivariate regression models examining the independent effects of gestational age, TFAP2B mRNA expression, and TFAP2B allele polymorphisms on the mRNA expression of genes involved with ductus closure in second trimester human ductus.

Gene	Regression coefficient (95% confidence interval)				
	Gestation [§]	TFAP2B mRNA [¶]	TFAP2B DNA polymorphism (present vs absent)		
			rs2817399(A)	rs2817419(G)	rs2635727(T)
<u>Calcium signaling</u>					
<i>CACNA1G</i> /Ca-alpha1G	<-0.07> (-.14 to .01)	0.33 * (.07 to .60)	<-0.59> * (-1.12 to -.05)	0.41 (-.02 to .84)	0.33 (-.10 to .78)
<i>CACNA1C</i> /CaLalpha1c	<-0.08> * (-.15 to -.01)	0.41 * (.16 to .66)	<-0.36> (-.90 to .19)		
<i>CACNB2</i> /CaLbeta2	<-0.10> * (-.18 to -.02)	0.42 * (.14 to .71)	<-0.63> * (-1.22 to -.03)	0.44 (-.04 to .92)	0.34 (-.16 to .83)
<i>RHOB</i>	0.23 * (.16 to .30)	0.37 * (.12 to .62)	<-0.12> (-.67 to .43)		
<u>K+ channels</u>					
<i>KCNA2</i> /Kv1.2	0.13 (-.23 to .02)	0.14 (-.41 to .68)	<-1.09> * (-2.15 to -.03)	0.76 (-.01 to .62)	<-0.62> (-.25 to 1.50)
<i>KCNA5</i> /Kv1.5	<-0.02> (-.07 to .04)	0.68 * (.49 to .87)	<-0.29> (-.82 to .25)		
<u>Contractile proteins</u>					
<i>CNN1</i> /Calponin	0.09 * (.04 to .13)	0.88 * (.72 to 1.03)	0.32 (-.25 to .89)		
<u>Endothelin signaling</u>					
<i>ECE1</i>	0.06 * (.01 to .12)	0.40 * (.21 to .58)	0.11 (-.32 to .55)		
<u>Prostaglandin signaling</u>					
<i>PDE1B</i>	0.05 (-.12 to .03)	0.44 * (.17 to .70)	0.46 (-1.02 to .11)		
<i>PDE3B</i>	0.00 (-.07 to .07)	0.72 * (.46 to .98)	0.11 (-.01 to .62)		
<i>PDE4D</i>	0.09 * (.01 to .17)	0.29 * (.01 to .57)	0.16 (-.75 to .42)		
<i>PTGIS</i> /PGI2-synthase	0.04 * (>.01 to .07)	0.67 * (.55 to .78)	0.01 (-.42 to .44)		
<u>Inflammation/remodeling</u>					
<i>EPAS1</i> /HIF2alpha	0.08 * (.02 to .13)	0.31 * (.11 to .50)	0.20 (-.29 to .69)		
<i>TFAP2B</i>	0.16 * (.09 to .22)	-	0.19 (-.36 to .73)		

[§] regression coefficient represents the increase in a gene's Δ CT for every increased week of gestation (multivariate analysis with TFAP2B Δ CT in the statistical model)

[¶] regression coefficient represents the increase in a gene's Δ CT for every increase in a unit of TFAP2B Δ CT (multivariate analysis with gestational age in the statistical model)

|| regression coefficient represents the increase in a gene's Δ CT when a TFAP2B allele (either: *rs2817399(A)*, *rs2817419(G)*, or *rs2635727(T)*) was present in the tissue (compared with when it was absent) (multivariate analysis with gestational age in the statistical model)

* $p<0.05$.

Table 3

Effects of immature gestational age, absence of betamethasone exposure, and presence of the TFAP2B *rs2817399* (A) allele on mRNA expression in the baboon and human ductus arteriosus.

Risk Factor	Immaturity [§]	No betamethasone [¶]	TFAP2B polymorphism <i>rs2817399</i> (A)
Gene	ΔCT	ΔCT	Regression coefficient
<u>Calcium signaling</u>			
<i>CACNA1G</i> /Ca-alpha1G	↓	↓	↓
<i>CACNA1C</i> /CaLalpha1c	-	-	-
<i>CACNB2</i> /CaLbeta2	↓	↓	↓
<i>RHOB</i>	-	-	-
<u>K⁺ channels</u>			
<i>KCNA2</i> /Kv1.2	↓	↓	↓
<i>KCNA5</i> /Kv1.5	↑	-	-
<u>Contractile proteins</u>			
<i>CNN1</i> /Calponin	↓	-	-
<u>Endothelin signaling</u>			
<i>ECE1</i>	↓	-	-
<u>Prostaglandin signaling</u>			
<i>PDE1B</i>	↓	↓	-
<i>PDE3B</i>	↓	↓	-
<i>PDE4D</i>	↓	-	-
<i>PTGIS</i> /PGI2-synthase	↓	-	-
<u>Inflammation/remodeling</u>			
<i>EPAS1</i> /HIF2alpha	↓	-	-
<i>TFAP2B</i>	↑	-	-

[§] ↑, ↓, -, ΔCT of immature ductus is significantly ($p < 0.05$) larger, smaller, or no different from the ΔCT of mature ductus (data from baboons, see Table 1).

[¶] ↑, ↓, -, ΔCT of immature ductus (not exposed to betamethasone) is significantly ($p < 0.05$) larger, smaller, or no different from the ΔCT of ductus exposed to betamethasone (data from baboons, see Table 1).

^{||} ↑, ↓, -, regression coefficients that represent a significant ($p < 0.05$) increase, decrease, or no significant change in a gene's ΔCT when the TFAP2B allele *rs2817399*(A) is present in the tissue (compared with when it is absent) (data from humans (see Table 2).